Mega menu

Home
Product regulation
Product regulation

Understand your obligations and access industry Guidance and other information about the products we regulate.
Safety and shortages
Safety and shortages

Access information about product recalls, shortages and other alerts, and learn how we manage safety.
Resources and guidance
Resources and guidance

Get information to help you understand our work, regulations and industry obligations.
Business services
Business services

Access our systems to submit applications, manage forms, make payments and communicate securely.

CSL Behring Australia Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

Cancellation by sponsor (77)
Prescription medicine registration (4)
Designation or determination (3)
Australian public assessment report (AusPar) (1)
Section 14, TGO91 consent (1)

Date

2025 (1)
2024 (2)
2023 (4)
2022 (10)
2021 (2)
2020 (3)
2019 (9)
2018 (4)
2017 (3)
2016 (2)
2015 (46)

Search

Sponsor content

86 result(s) found, displaying 31 to 40

CSL New Zealand Rh(D) Immunoglobulin-VF (Human Anti-D Rho Immunoglobulin), solution for injection, vial Cancelled under Section 30(1)(c) of the Act

25 February 2019

Cancellation by sponsor

Requested by CSL Behring Australia Pty Ltd
HIZENTRA (CSL Behring Australia Pty Ltd)

11 September 2018

Prescription medicine registration

Active ingredients: normal immunoglobulin.
Pakistan Intragam P Normal Immunoglobulin (Human) 6% (6 g/100 mL), 50 mL Solution for Intravenous Infusion Cancelled under Section 30(1)(c) of the Act

10 August 2018

Cancellation by sponsor

Requested by CSL Behring Australia Pty Ltd
BERINERT SC (CSL Behring Australia Pty Ltd)

9 July 2018

Prescription medicine registration

Active ingredients: C1 esterase inhibitor.
AusPAR: Lonoctocog alfa (rch)

8 February 2018

Australian public assessment report (AusPar)

Australian Public Assessment Report for Lonoctocog alfa (rch)
CSL Behring Australia Pty Ltd - Medicine administration kit, percutaneous, medicated, single-use Cancelled under s41GL(d) of the Act

2 November 2017

Cancellation by sponsor

Requested by CSL Behring Australia Pty Ltd
"TBSF" Prothrombin Complex Concentrate 500 IU, Powder for injection Cancelled under s30(1)(c)

13 September 2017

Cancellation by sponsor

Requested by CSL Behring Australia Pty Ltd
CSL Taiwan Biostate, Human Coagulation Factor VIII, freeze-dried 250 IU powder for injection vial Cancelled under s30(1)(c)

13 September 2017

Cancellation by sponsor

Requested by CSL Behring Australia Pty Ltd
"TBSF" High Purity Factor VIII Concentrate Cancelled under s30(1)(c)

13 December 2016

Cancellation by sponsor

Requested by CSL Behring Australia Pty Ltd
CSL Behring Australia Pty Ltd - Medication transfer set Cancelled under s41GL(d) of the Act

4 November 2016

Cancellation by sponsor

Requested by CSL Behring Australia Pty Ltd

Pages

First page
Previous page
Page 1
Page 2
Page 3
Current page 4
Page 5
Page 6
Page 7
Page 8
Page 9
Next page
Last page

Using our website

Accessibility
Privacy
Security
Disclaimer
Copyright
Freedom of information
Acronyms and glossary terms

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Email subscriptions
Contact us
Facebook
(formerly Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health, Disability and Ageing acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.